PL

Plumbline Life Sciences, Inc.

Develops DNA vaccines and therapeutics for companion animals and livestock.

222670 | KO

Overview

Corporate Details

ISIN(s):
KR7222670002
LEI:
Country:
South Korea
Address:
서울특별시 서초구 반포대로 222성의교정 성의회관 1315호, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plumbline Life Sciences, Inc. is an animal biopharmaceutical company that develops a new class of nucleic acid-based DNA medicines. Utilizing its proprietary DNA platform technology, the company creates vaccines and therapeutics for the global animal health market, targeting both companion animals and livestock. Its development pipeline includes 'Renewdog', a first-in-class DNA therapeutic for canines, and other products for applications such as oncology and infectious disease prevention. The company's technology is designed to produce potent, safe, and room-temperature stable treatments with a simplified manufacturing process.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-12 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2025-06-11 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.3 KB
2025-06-02 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 32.5 KB
2025-05-29 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-05-16 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 19.7 KB
2025-05-12 00:00
Share Issue/Capital Change
전환청구권행사
Korean 16.5 KB
2025-04-28 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 40.7 KB
2025-04-07 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 41.6 KB
2025-04-07 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 40.2 KB
2025-04-03 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 18.3 KB
2025-03-28 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 31.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 17.9 KB
2025-03-26 00:00
Remuneration Information
주식매수선택권부여에관한신고
Korean 20.6 KB
2025-03-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.6 KB
2025-03-19 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 299.7 KB

Automate Your Workflow. Get a real-time feed of all Plumbline Life Sciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Plumbline Life Sciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Plumbline Life Sciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.